Trials / Completed
CompletedNCT00143351
Mozart Relapse Study
Open Extension Study Evaluating the Long-term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of oral Ziprasidone
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziprasidone |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-09-01
- First posted
- 2005-09-02
- Last updated
- 2021-02-21
Locations
16 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00143351. Inclusion in this directory is not an endorsement.